by Mybiogate | Sep 18, 2020 | Industry Research
Author: Ginger Ding The rate of return on investment in new drugs has steadily declined; it is imperative to improve R&D efficiency New drug research and development has three characteristics that may raise concerns: high cost (985.3 million [1]), a long... by Mybiogate | Sep 17, 2020 | Industry Research
Author: Ginger Ding On September 4, 2020, I-Mab Biopharma announced a collaboration with AbbVie on the global development and commercialization of CD47 monoclonal antibody TJC4. The US$2.9 billion collaboration signifies the largest out-licensing in the history... by Mybiogate | Sep 16, 2020 | Industry Research
The global pediatric drug market has steady growth with China ranking second The global pediatric drug and vaccine market was valued at approximately US$122 billion in 2019. By 2025 it is expected to reach US$141 billion, with a compound annual growth rate of 2.4%. At... by Mybiogate | Sep 15, 2020 | Chinese company profile
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 2019 Revenue: US$4.17 Billion Number of Employees: 28,000+ Founded: 1994 Overview Fosun Pharma (stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.... by Mybiogate | Sep 15, 2020 | Industry Research
Ginger Ding, Chen Lixing Introduction “Industry Research | Pediatric Drug Market and Cross-border Collaboration Trends (Part 1)” reviews the latest legislation and incentive measures that aim to promote the development of the pediatric...